Radius (RDUS) Collaborates With Novartis Targeting Cancer
Radius Health, Inc. RDUS announced a worldwide collaboration with Novartis AG NVS for the evaluation of the efficacy and safety of combining its RAD1901 with Novartis’ LEE011 (ribociclib).
Under the collaboration agreement, Radius and Novartis will provide compound material and resources for the studies to be conducted and will share third party out-of-pocket research and development expenses. The agreement is non-exclusive. The companies also plan to conduct pre-clinical studies on the combination of RAD1901 and BYL719 (alpelisib).
We note that RAD1901 is currently in an open-label, two-part, dose-escalation, phase I study in postmenopausal women who are suffering from advanced estrogen receptor positive and HER2 negative breast cancer.
Additionally, Radius is conducting a phase IIb study on the candidate for the treatment of vasomotor symptoms.
Meanwhile, we expect investor focus to remain on the company’s regulatory progress with its lead pipeline candidate, abaloparatide. Abaloparatide subcutaneous (SC) is currently under regulatory review in the EU for the treatment of osteoporosis in postmenopausal women. Radius is looking for a commercialization partner for abaloparatide and intends to file for FDA approval by the end of this quarter.
Radius is also looking to develop a short wear time transdermal patch of abaloparatide - a human replicative study was initiated in Dec 2015 with data read-out expected in mid-2016.
Radius is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the health care sector are Auris Medical Holding AG EARS and Corcept Therapeutics Incorporated CORT. Both carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
CORCEPT THERAPT (CORT): Free Stock Analysis Report
RADIUS HEALTH (RDUS): Free Stock Analysis Report
AURIS MEDICAL (EARS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
